Binding domain-immunoglobulin fusion proteins
AssigneeTrubion Pharmaceuticals, Inc.
InventorsJeffrey Ledbetter, Martha Hayden-Ledbetter
Life of this patent
Estimating the term…
Abstract
The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
Claims110
A method of treatment, comprising administering to a subject in need thereof a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a single chain protein that binds to a CD37, wherein said single chain protein comprises:
- (a) a binding domain polypeptide capable of binding to CD37, said binding domain polypeptide being joined to
- (b) a hinge peptide, said hinge peptide being joined to
- (c) an immunoglobulin heavy chain CH2 constant region polypeptide, said CH2 constant region polypeptide being joined to
- (d) an immunoglobulin heavy chain CH3 constant region polypeptide,
- wherein said single chain protein is capable of mediating at least one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and complement fixation.
Dependencies are inferred from the claim text.